CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (36,794)	$ (20,100)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	5,657	1,492
Depreciation and amortization	685	209
Accretion on debt		1,578
Accretion on marketable securities	615
Fair value adjustments on embedded debt derivatives		(995)
Interest on capital lease	57	12
Gain on fixed asset disposal	(29)
Issuance of common stock for Alvaxa acquisition		541
Gain on debt extinguishment	(567)	(45)
Changes in operating assets and liabilities:
Prepaid expenses	828	(1,124)
Other assets	(327)	361
Accounts payable and accrued liabilities	(1,426)	335
Accrued interest		53
Compensation and employee benefits	837	(271)
Other liabilities	205	249
Net cash used in operating activities	(30,259)	(17,705)
Investing activities
Purchases of property and equipment	(2,026)	(1,206)
Proceeds from property and equipment disposals	318
Purchases of short-term investments	(183,669)
Sales of short-term investments	11,259
Maturities of short-term investments	31,000
Alvaxa IPR&D acquisition		(197)
Net cash used in investing activities	(143,118)	(1,403)
Financing activities
Proceeds from the PPP loan		567
Proceeds from the exercise of common stock warrants and options	29	20
Deferred offering costs		(2,105)
Purchases Related to Employee Stock Purchase Plan	80
Capital lease payments	(255)	(41)
'Proceeds on the from issuance of common stock upon initial public offering, net of issuance costs	140,594
Net cash provided by financing activities	163,940	35,453
Net (decrease) increase in cash and cash equivalents	(9,437)	16,345
Cash and cash equivalents at beginning of period	16,596	251
Cash and cash equivalents at end of period	7,159	16,596
Supplemental disclosure of noncash financing information:
Property and equipment additions included in accounts payable and accrued liabilities		204
Deferred offering costs included in accounts payable and accrued liabilities		1,207
Interest on financing	57	12
Convertible preferred stock issued in exchange for note redemption		18,050
Conversion of Series A, B, C, D, E, F Convertible Preferred Stock into Common Stock
Supplemental disclosure of noncash financing information:
Conversion of stock		47,545
Conversion Of Series AA and BB Convertible Preferred Stock Into Common Stock Member
Supplemental disclosure of noncash financing information:
Conversion of stock	95,826
Conversion of Common Stock into Series AA Convertible Preferred Stock
Supplemental disclosure of noncash financing information:
Conversion of stock		17,274
Series AA Convertible Preferred Stock
Financing activities
Proceeds on the issuance of convertible preferred stock		26,087
Series BB Convertible Preferred Stock
Financing activities
Proceeds on the issuance of convertible preferred stock	$ 23,492	$ 10,925